WT1 is Differentially Expressed in Serous, Endometrioid, Clear Cell, and Mucinous Carcinomas of the Peritoneum, Fallopian Tube, Ovary, and Endometrium

International Journal of Gynecological Pathology

Volumn 23, Issue 2, 2004, Pages 110-118

  Acs, Geza ^a   Pasha, Theresa ^a   Zhang, Paul J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Endometrial carcinoma; Fallopian tube carcinoma; Ovarian carcinoma; Primary peritoneal carcinoma; Serous carcinoma; Wilms' tumor gene; WT1

Indexed keywords

PROTEIN P53; WT1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CELL DIFFERENTIATION; CLEAR CELL CARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CLEAR CELL CARCINOMA; ENDOMETRIUM ENDOMETRIOID CARCINOMA; ENDOMETRIUM SEROUS CARCINOMA; FALLOPIAN TUBE ENDOMETRIOID CARCINOMA; FALLOPIAN TUBE SEROUS CARCINOMA; FEMALE; FEMALE GENITAL TRACT CANCER; GENE EXPRESSION; HISTOLOGICAL SUBTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MESOTHELIOMA; MUCINOUS CARCINOMA; NEPHROBLASTOMA; OVARY CARCINOMA; OVARY CLEAR CELL CARCINOMA; OVARY ENDOMETRIOID CARCINOMA; OVARY MUCINOUS CARCINOMA; OVARY SEROUS CARCINOMA; PERITONEUM TUMOR; PRIMARY PERITONEUM SEROUS CARCINOMA; PRIORITY JOURNAL; SEROUS CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE TUBE CARCINOMA; WT1 GENE;

AGED; CARCINOMA; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; WT1 PROTEINS;

EID: 1642398624     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-200404000-00004     Document Type: Article

References (54)

1. Hastie ND. The genetics of Wilms' tumor-a case of disrupted development. Annu Rev Genet 1994;28:523-58.
2. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-20.
3. Schamhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001;273:141-61.
4. Lee SB, Haber DA. Wilms' tumor and the WT1 gene. Exp Cell Res 2001;264:74-99.
5. Pelletier J, Schalling M, Buckler AJ, et al. Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev 1991;5:1345-56.
6. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990;346:194-7.
7. Zhou J, Rauscher FJ 3rd, Bondy C. Wilms' tumor (WT1) gene expression in rat decidual differentiation. Differentiation 1993;54:109-14.
8. Charles AK, Mal S, Watso J, et al. Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: An immunohistochemical study. Mol Pathol 1997;50:138-44.
9. Hosono S, Gros, I, English MA, et al. E-cadherin is a WT1 target gene. J Biol Chem 2000;275:10943-53.
10. Mayo MW, Wang CY, Drouin SS, et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 1999;18:3990-4003.
11. Maheswaran S, Englert C, Bennett P, et al. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 1995;9:2143-56.
12. Maheswaran S, Par S, Bernard A, et al. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A 1993;90:5100-4.
13. Vandamme B, Lissens W, Amfo K, et al. Deletion of chromosome 11p13-11p15.5 sequences in invasive human ovarian cancer is a subclonal progression factor. Cancer Res 1992;52:6646-52.
14. Viel A, Giannini F, Tumiotto L, et al. Chromosomal localisation of two putative 1 lp oncosuppressor genes involved in human ovarian tumours. Br J Cancer 1992;66:1030-6.
15. Makar AP, Baekelandt M, Trope CG, et al. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:175-80.
16. Kvale G, Heuch I, Nilssen S, et al. Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer 1988;42:246-51.
17. Deligdisch L, Holinka CF. Endometrial carcinoma: two diseases? Cancer Detect Prev 1987;10:237-46.
18. Caduff RF, Svoboda-Newman SM, Bartos RE, et al. Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. Am J Surg Pathol 1998;22:319-26.
19. Ronnett BM, Zaino R, Ellenson LH, et al. Endometrial carcinoma. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. New York: Springer-Verlag, 2002:501-59.
20. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002;117:541-5.
21. Wheeler JE. Diseases of the fallopian tube. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. New York: Springer-Verlag, 2002:617-48.
22. Scull RE, Young RH, Clement PB. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Atlas of Tumor Pathology, 3rd series, fascicle 23. Washington, DC: Armed Forces Insfitute of Pathology, 1998.
23. Drummond IA, Madden SL, Rohwer-Nutter P, et al. Repression of the insulin-like growth factor II gene by the Wilms' tumor suppressor WT1. Science 1992;257:674-8.
24. Wemer H, Re GG, Drummond IA, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms' tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms' tumor gene product. Proc Natl Acad Sci U S A 1993;90:5828-32.
25. Gashler AL, Bonthron DT, Madden SL, et al. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms' tumor suppressor WT1. Proc Natl Acad Sci U S A 1992;89:10984-8.
26. Dey BR, Sukhatme VP, Roberts AB, et al. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol 1994;8:595-602.
27. Hewitt SM, Hamada S, McDonnell TJ, et al. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 1995;55:5386-9.
28. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms' tumor gene (WT1) in human leukemia. Blood 1997;89:1405-12.
29. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-9.
30. Loeb DM, Evron E, Patel CB, et al. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 2001;61:921-5.
31. Silberstein GB, Van Horn K, Strickland P, et al. Altered expression of the WT1 Wilms' tumor suppressor gene in human breast cancer. Proc Natl Acad Sci U S A 1997;94:8132-7.
32. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002;8:1167-71.
33. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999;90:194-204.
34. Makrigiannakis A, Coukos G, Mantani A, et al. Expression of Wilms' tumor suppressor gene (WT1) in human endometrium: regulation through decidual differentiation. J Clin Endocrinol Metab 2001;86:5964-72.
35. Bruening W, Gros P, Sato T, et al. Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest 1993;11:393-9.
36. Schorge JO, Miller YB, Qi LJ, et al. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol 2000;76:369-72.
37. Gessler M, Konig A, Bruns GA. The genomic organization and expression of the WT1 gene. Genomics 1992;12:807-13.
38. Viel A, Giannini F, Capozzi E, et al. Molecular mechanisms possibly affecting WT1 function in human ovarian tumors. Int J Cancer 1994;57:515-21.
39. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203-14.
40. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000;19:158-63.
41. Shevchuk MM, Lallas TA, DaSilva M. Endometrial carcinoma: do oncogene studies separate types I and II. Mod Pathol 2003;16:211A.
42. Zhang Q, Wright T, Alexis D, et al. Differential expression of WT1 in uterine serous and endometrioid carcinoma. Mod Pathol 2003;16:217A.
43. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.
44. Klemi PJ, Pylkkanen L, Kiilholm P, et al. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8.
45. Ichikawa Y, Nishida M, Suzuki H, et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 1994;54:33-5.
46. Pere H, Tapper J, Wahlstrom T, et al. Distinct chromosomal imbalances in uterine serous and endometrioid carcinomas. Cancer Res 1998;58:892-5.
47. Tapper J, Butzow R, Wahlstrom T, et al. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Br J Cancer 1997;75:1782-7.
48. Tapper J, Sarantaus L, Vahteristo P, et al. Genetic changes in inherited and sporadic ovarian carcinomas by comparative genomic hybridization: extensive similarity except for a difference at chromosome 2q24-q32. Cancer Res 1998;58:2715-9.
49. Pere H, Tapper J, Seppala M, et al. Genomic alterations in fallopian tube carcinoma: comparison to serous uterine and ovarian carcinomas reveals similarity suggesting likeness in molecular pathogenesis. Cancer Res 1998;58:4274-6.
50. Hofmann W, Royer HD, Drechsler M, et al. Characterization of the transcriptional regulatory region of the human WT1 gene. Oncogene 1993;8:3123-32.
51. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms' tumor gene (wtl) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060-7.
52. Gaiger A, Carter L, Greinix H, et al. WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res 2001;7:761s-5s.
53. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 2001;73:177-87.
54. Tsuboi A, Oka Y, Ogawa H, et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000;20:195-202.